Checks genetic markers to classify cervical cancer risk
Tests genetic markers in people undergoing routine cervical cancer screening.
Plain-language title generated from the registry record
Registry title: Cervical Cancer Susceptible Population Classification
Key facts
- Where
- Hefei, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women at average risk of cervical cancer who plan to have a screening colposcopy and agree to a blood draw and five years of follow-up.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Average risk for cervical cancer, as judged by a doctor or healthcare provider. No cervical cancer.
- Earlier treatment
- Must not currently take anti-cancer drugs or disease-modifying anti-rheumatic drugs.
Main reasons for not taking part
- History of cervical cancer
- History of any cancer (with a limited exception for skin squamous cell cancer removed at least 12 months before consent)
- Currently taking anti-cancer or disease-modifying anti-rheumatic drugs
- Major physical trauma, surgery, organ transplant or blood transfusion in the 30 days before consent
- Any medical condition the investigator thinks should rule out joining
Read by machine on 9 November 2026.
Where in China
- The First Affiliated Hospital of USTCHefei, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Anhui Provincial Hospital
- Trial code
- NCT06405945
- Record updated
- 9 May 2024
- Original description
Cervical cancer is the third most common lethal tumor globally, causing around a quarter million deaths annually, despite the availability of HPV vaccines. Recent Genome-wide association studies (GWAS) have identified numerous genetic markers linked to cervical cancer, including rs10175462, rs10007915, rs35721900, and rs61646675, which have been verified as being related to susceptibility to cervical cancer. However, many reports lack clarity, consistency, and validation. In this comprehensive study, we will analyze the genomic risk factors associated with cervical cancer, classify individuals into different risk categories, and explore potential biomarkers and therapeutics.Read full original descriptionShow less
Evalutaion of the SNPs Test in Average Cervical Cancer Screening Episode
Cervical cancer is the third most common lethal tumor globally, causing around a quarter million deaths annually, despite the availability of HPV vaccines. Recent Genome-wide association studies (GWAS) have identified numerous genetic markers linked to cervical cancer, including rs10175462, rs10007915, rs35721900, and rs61646675, which have been verified as being related to susceptibility to cervical cancer. However, many reports lack clarity, consistency, and validation. In this comprehensive study, we will analyze the genomic risk factors associated with cervical cancer, classify individuals into different risk categories, and explore potential biomarkers and therapeutics.
Inclusion: Subjects aged >=18 years at time of consent; Intended to undergo screening colposcopy; Considered by a physician or healthcare provider as being of "average risk" for cervical cancer; Willing to consent to blood draw cervical disease treatments; Willing to sonsent to follow-up for five years as per protocol.
Exclusion: History of any malignancy (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study); Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs; Any major physical trauma (e.g. disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent; History of cervical cancer; Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study.